In a 37-year-old male with genetically confirmed Bardet-Biedl Syndrome (BBS10 compound heterozygous variants), sequential therapy with liraglutide then setmelanotide produced a combined 10.5% weight reduction from baseline BMI 35.2 kg/m², normalized liver transaminases, reduced liver stiffness, sustained urinary albumin-to-creatinine ratio improvement, and stable eGFR over 12 months. HOMA-IR improved sufficiently to permit discontinuation of metformin and statin, while two small interventional studies (n≈10–40) corroborated reductions in metabolic syndrome burden and liver steatosis.
The significance here extends well beyond a single case. BBS is a ciliopathy affecting primary cilia signaling, and its obesity phenotype is driven by hypothalamic MC4R pathway dysfunction — a mechanism fundamentally distinct from garden-variety leptin resistance or lifestyle-driven adiposity. This makes MC4R agonism mechanistically targeted rather than symptomatic, which likely explains the organ-level benefits observed independent of weight change magnitude. The albuminuria improvement is particularly compelling: GLP-1 receptor agonists already carry reno-protective evidence in diabetic nephropathy, and seeing a similar signal from MC4R agonism in a non-diabetic syndromic context hints at shared downstream anti-inflammatory or hemodynamic pathways worth investigating.
Critical limitations are substantial: this is a single-patient case report with no control arm, confounded by concurrent polypharmacy changes. Real-world adult BBS cohorts are vanishingly small globally. Clinicians should treat these findings as hypothesis-generating. For the rare-disease field, however, this is a meaningfully encouraging data point supporting prospective registry studies of setmelanotide's cardiometabolic and nephroprotective profile in ciliopathy patients.